close price hkd jan
one-stop platform fuel global
lead global drug develop platform initi buy
wuxi apptec wuxi lead global one-stop solut platform
innov drug forecast wuxi revenu compound-annual-growth-rate
normal net profit exclud non-recur item compound-annual-growth-rate
ep back wuxi fast
growth prospect uniqu one-stop servic global lead posit
initi coverag buy sotp-bas target price impli
share-pric upsid pe also see downsid risk slowdown
invest innov drug global
growth consist ahead industri averag
revenu growth acceler significantli beat global
domest industri averag owe fast-grow busi driven
rise demand long-tail domest client rapid transform
early-phas develop busi commerci manufactur
growth boom china ride wave domest innov
biotech innov boom china revenu gener domest
client grow rapidli yoy believ china client
key driver wuxi share wuxi revenu increas
new success-bas busi domest
discoveri servic unit ddsu launch provid one-stop solut
small-molecul new drug discoveri investig new drug ind
submiss revenu consist servic fee plu mileston incom and/or
recur royalti deriv forward equiti valuat mileston incom
royalti use risk-adjust dcf methodolog
cell/gen therapi clinic cro contract research two busi
highli promis market potenti may becom wuxi next growth engin
still nascent global outsourc market cell/gen therapi
servic gather momentum revenu compound-annual-growth-rate
clinic cro account wuxi revenu gross margin
much lower lead peer eg tigerm show signific potenti
improv expect wuxi expand global presenc via
huatai financi hold hong kong limit abbrevi huatai hk throughout report
pleas refer end page analyst certif requir disclosur
comprehens platform enabl drug
wuxi boast industry-b growth
china busi becom major growth
rais sehk
assum coverag buy target price
wuxi advantag comprehens uniqu one-stop
growth develop
differ strength china- us-bas lab
transfer low-cost economi golden time china
clinic cro enhanc profit
growth engine-i improv output per
vc invest steadi deal flow high
qualiti talent attract train
build expand reach within healthcar
earn analysi
work capit analysi
risk view
busi overview wuxi
comprehens platform enabl drug innov
wuxi apptec wuxi lead open-access platform provid one-stop solut
drug
manufactur well gene/cel therapi expect becom wide
adopt futur platform character high-valu combin
cutting-edg technolog lead talent around year experi small-
molecul new drug develop aim lower barrier entri
drug innov improv effici reduc cost divis
note dmpk drug metabol pharmacokinet adm absorpt distribut metabol excret
wuxi boast industry-b growth rate
wuxi largest servic china-bas market player term discoveri pre-
clinic small molecul contract manufactur organ second-
largest market player cell/gen therapi servic us despit larg scale
wuxi consist achiev growth exceed industri averag mainli attribut
increas custom penetr execut long-tail china strategi
enlarg coverag new custom expand busi line eg
cell/gen therapi servic small molecul capac in-hous
 acquisit
cro wuxi beat global china market growth
wuxi beat global china market growth
wuxi market leader field oper
note number circl rank wuxi market
china busi becom major growth driver
revenu client china record compound-annual-growth-rate
acceler attribut strong growth ddsu clinic cro
busi wuxi place great import china strategi expect fast
growth proport revenu deriv emerg drug outsourc
market china increas profit new busi model ddsu
driver domest busi ramp
china enter new era drug innov full rang valu chain
support drug develop undergo rapid develop seen trend
develop wuxi revenu gener domest client
acceler yoy china client account greater
share wuxi revenu vs becom
revenu client china
revenu breakdown custom locat
sinc wuxi engag deeper collabor china client success-
base mode share intellectu properti ip revenu gener three
way servic fee one-off fee tradit pre-ind servic npm
downstream mileston incom one-off fee either mileston reach eg
phase-i trial pass fee upon licens drug npm royalti
recurr incom drug commerci typic amount annual
wuxi submit ind applic custom eight
yet project royalti fee structur advanc commerci
howev project cash flow increas project enter mileston
royalti stage
illustr profit pattern ddsu busi
besid two major segment pre-ind research manufactur servic
two busi strong market potenti see rapid growth
clinic servic cell/gen therapi opinion may becom
next growth engin wuxi
strong growth potenti cell gene therapi
new field pharmaceut industri cell/gen therapi experienc
unpreced develop accord frost sullivan research servic still
earli stage develop global pharmaceut research outsourc
market rapidli gather momentum revenu compound-annual-growth-rate
first mover wuxi provid high-qual process develop servic
gain accord ipo prospectu lead posit industri
revenu global/u market rank fourth/second
breakdown drug outsourc market
cell gene therapi servic grow rapidli
strong growth potenti clinic servic
accord frost sullivan clinic servic constitut major cro market
global market china market account
wuxi revenu captur growth opportun support clinic trial
global compani strive expand busi either via self-built develop
 acquir share researchpoint global octob
acquir remain share order build wuxi intern multi-
blueprint develop wuxi smo site offic
rais sehk list
wuxi list sehk decemb issu share
share over-allot initi offer
over-allot option proce mainli assign
capac expans cro cmo/cdmo contract develop
h-share issuanc intend usag
amount net fundrais hkdmn
expans capac capabl across busi unit
fund acquisit cro cmo/cdmo compani
invest ecosystem invest incub compani innov busi model
develop cutting-edg technolog
repay select bank loan
work capit gener corpor purpos
fundrais
assum coverag buy target price
expect wuxi world-lead uniqu one-stop solut platform achiev
normal net profit compound-annual-growth-rate exceed exclud non-recur item
mainli driven rise demand long-tail domest client
rapid
mass
commerci project ep
assum ep contribut fair valu chang ventur capit
transform early-phas develop busi
initi coverag wuxi buy target price base sum-
of-the-part sotp valuat valu tradit cro/cmo busi
refer share peer averag pe valu ddsu
mileston royalti incom risk-adjust dcf valu ventur capit
invest project fair equiti valu wuxi correspond
pe base ep
wuxi core busi divid four part china-bas lab servic
hit gener optim drug test eg dmpk/adm toxicolog
scale-up us-bas lab servic medic devic test ensur complianc
gmp guidelin cell/gen
therapy-rel develop gmp
oper statist analysi medic write site manag
manufactur servic provid process develop mass product
advanc intermediari api clinic trial commerci launch
look differ client group see china client mid-
sized/start-up firm becom signific compani revenu
revenu breakdown busi
revenu breakdown custom
note top mnc refer wuxi top client
wuxi sustain robust growth china-bas pre-ind servic see
sustain growth account revenu continu margin
improv except us-bas lab mainli due invest cell/gen
therapi rapid growth clinic servic cell therapi though
partial off-set medic devic test busi us-bas lab
strong perform wuxi core busi
note clinic servic exclud incom reagent
revenu revenu
revenu revenu
revenu revenu
wuxi advantag comprehens uniqu one-stop platform
wuxi provid comprehens end-to-end servic across new drug develop
process contrast tradit giant special cro eg iqvia charl
river tigerm eg lonza asymchem wuxi enabl
one-stop solut meet differ need drug innov valu chain start-
up wuxi provid cutting-edg technolog experi capac equip
big pharma wuxi provid multi-unit packag servic well higher
effici develop
comparison servic suppli global domest giant
accord frost sullivan wuxi pre-ind cro servic take lead
posit global revenu china market
pre-ind servic offer two region china china-bas lab small-molecul
develop us us-bas lab devic test cell/gen therapi
busi achiev sustain growth revenu compound-annual-growth-rate
significantli consist beat industri averag
global market size pre-ind cro
china market size pre-ind cro
note includ wuxi revenu china-bas us-bas lab
note includ wuxi revenu china-bas lab
anticip strong momentum continu driven acceler growth
revenu higher profit attribut domest innov demand long-tail
client busi line expans boom market demand cell/gen
therapi us
revenu forecast china- us-bas lab
growth develop strategi
view wuxi develop four import strategi support futur growth
pre-ind servic provid one-stop solut cross-sel company-
wide platform establish long-tail custom profil continu expans
busi line har grow opportun china
provid one-stop solut cross-sel company-wid platform
screen lead optim drug test eg chemic biolog analysi
vitro vivo keep increas client penetr provid multi-servic
packag cutting-edg technolog instanc wuxi establish global
lead dna encod librari del dna barcod
dramat improv screen effici week vs month thu see
wuxi maintain high level client loyalti gener increas
wuxi built long-tail custom pattern start-up region client
aggreg gradual make larger proport wuxi sale
past three year client despit smaller scale contain signific
untap revenu potenti target drug move later stage
month end june wuxi provid servic client
retent multi-national corpor mnc
merck roch revenu repeat custom
custom use servic one function unit compani gain
new client abil continu gain new custom key growth engin
view
illustr wuxi long-tail client profil
sustain develop long-tail client
mid-siz start-up
note mnc refer wuxi top client
note mnc refer wuxi top client
continu expans busi line
maintain lead posit drug discoveri wuxi seek opportun
build new function unit center drug test chengdu bioequival
servic suzhou construct cutting-edg cell therapi research servic
also one area wuxi focus ride futur trend constantli updat
function wuxi well place deliv state-of-the-art servic meet client need
rapidli chang environ view
qidong chemic biolog lab
viral vector plasmid dna
cell gene therapi
cell- gene-therapi
expans nationwid
coverag clinic research
philadelphia cgmp manufactur cell-
expand smo clinic research platform
establish big data analysi platform
establish nation clinic research
combin intermedi research platform
expect start oper
har grow opportun china
import develop strategi wuxi target china market market
rank second world-wide size global drug revenu maintain
steadi growth rate yoy howev china emerg market
pharmaceut sector undergo industri restructur shift low-end
gener high-end innov drug strong demand innov
substanti expens defici technolog experi togeth
creat blue ocean outsourc market wuxi leverag domest advantag
brand power client pool talent sourc fuel sustain growth
global china pharmaceut market size
 invest continu increas china
differ strength china- us-bas lab
china-bas lab focu small molecul discoveri test sector achiev
strong growth revenu compound-annual-growth-rate expect momentum
continu next three year given wuxi close relationship
grow incom larg pharmaceut emerg biotech compani china
new busi model ddsu whose busi much profit
start account larger revenu share new client especi start-up
promis growth potenti releas capac servic line start
wuxi china-bas lab revenu gross margin estim
china-bas servic charg three differ way full-tim equival fte
fee-for-servic ff ddsu due greater input talent and/or intellectu
properti fte ddsu enjoy stronger client sticki higher profit eg
gm fte servic vs ff
busi model china-bas lab
fee-for-servic ff charg item
charg time
polici
hatch
wuxi leverag sizabl databas experi gain engag
success-bas collabor domest custom one-stop solut provid
fee charg three way sometim fee structur combin
servic fee one-off fee tradit pre-ind servic npm mileston
incom one-off fee either mileston reach fee upon licens
drug npm royalti recurr incom commerci
typic amount annual sale npm
wuxi appli ind custom eight
receiv cta approv yet project royalti fee structur advanc
commerci howev project cash flow increas margin lift
project enter mileston royalti stage
project fair valu wuxi ddsu busi around mainli
base four assumpt project undergo clinic trial year first
project receiv royalti overal pass rate phase-i new drug
applic nda china food drug administr cfda higher
us fda assum model peak sale one small-molecul
new drug averag plateau four year
number item
new cta
cta approv
rmbmn revenu new launch rmbmn
illustr sale pattern innov small-molecul drug
dcf valuat ddsu busi
pv ncf
pv termin valu
us-bas lab cell gene therapi
us-bas lab wuxi provid two type servic cell gene therapi
facilit innov develop autolog allogen cell therapi car-t
cell therapi oncolyt viru medic devic test offer test
develop medic devic cgmp good laboratori practic glp
facil enabl client stay forefront devic technolog variou
introduct cell therapi
introduct gene therapi
wuxi cell gene therapi servic
wuxi leverag core compet establish market leadership
emerg area market share us cell therapi wuxi
assist custom phase-i seven phase-ii/iii clinic trial
us cell gene therapi outsourc market
wuxi demonstr stabl revenu growth past four year us-bas
lab revenu compound-annual-growth-rate howev experienc declin
margin mainli due higher labor cost continu invest cell therapi
platform believ compani achiev sustain growth near futur
revenu compound-annual-growth-rate project gm may drag
one-off loss big device-test custom due corpor
restructur due invest newly-built facil cell therapi
long-term growth margin recoveri given capac releas cell
wuxi us-bas lab revenu gross margin estim
lead cdmo/cmo supplier domest market market
share accord frost sullivan sta wuxi platform
demonstr much higher growth rate industri averag revenu
compound-annual-growth-rate vs china industri averag forecast strong growth
continu mostli driven higher market potenti early-phas project
move commerci releas new capac first-mov advantag
har opportun market author holder mah polici
wuxi cmo/cdmo revenu gross margin estim
transfer low-cost economi golden time china
drug manufactur outsourc sizabl highli decentr market
display steadi growth past revenu compound-annual-growth-rate
project increas slightli mostli driven fast growth
emerg market china revenu compound-annual-growth-rate
domest market size china
breakdown global market
breakdown china market
note lonza consid revenu pharma biotech sector
progress develop commerci
leverag state-of-the-art technolog except talent base wuxi deliv
higher value-ad servic process develop formul optim
tradit domest busi simpli copi exist
manufactur process busi benefit client offer
better qualiti effici sometim lower cost
comparison tradit
type servic
larg scale
develop
capac construct
copi process
technolog pharmaceut
compani basic
innov technolog
process innov
chemic structur
provid custom
technic barrier type industri custom retent profit margin
capit intens poor
strong cgmp api
technolog
sta provid advanc intermediari activ pharmaceut
ingredi api commerci product build capac expans
strong reput sta also expect begin mass product chemic
prepar complex formul impli larger incom higher
increas volum revenu manufactur servic move later phase
multipl barrier entri
lead global player eg lonza patheon primarili focu
prepar advanc api domest cmo still catch cgmp
intermedi view sta effort start mass product drug
prepar high gear think four major barrier entri domest
cmo sta advantag well-establish stabl quality-control
system capabl late-stag process develop cgmp-standard capac
sta first china-bas small molecul platform author regul
us eu canada capabl process valid well-earn
reput custom loyalti
strength suppli global domest giant
substanti high-potenti project pool
compani project pre-clin phase stage
phase ii stage phase stage commerci manufactur stage
larg number early-phas project bode well long-term growth
continu move later phase deeper collabor higher
royalti plu opportun sign new project posit feedback loop may
kick
wuxi number project differ stage
project transfer earli later stage
preclin phase
new capac construct
wuxi achiev util rate overal reactor
around liter new capac construct changzhou
expect increas overal volum liter believ changzhou factori
unleash growth mass product short medium term
wuxi new capac construct
note compani continu work changzhou factori plan capac nine workshop
three alreadi oper
first mover captur growth opportun mah
april cfda announc mah pilot program provinces/region
includ beij shanghai jiangsu manufactur outsourc embrac new
opportun sinc author licens holder necessarili engag commerci
product sta benefit first mover sta support first
two innov drug approv mah system ganovo-ascleti june
aiyoute-hutchison septemb accord shanghai food
drug administr sta particip four project mah drug
pilot drug mah system shanghai batch
dulera oral
fluticason
propion powder
shanghai food drug administr websit huatai hk research
clinic cro enhanc profit
clinic research servic account largest proport cro busi world-wide
global market share accord frost sullivan new entrant
wuxi period rapid develop revenu compound-annual-growth-rate
believ rapid pace growth sustain mainli driven high demand
fast-grow clinic cro market china still-consider room wuxi
improv output per capita continu activ
wuxi clinic research other revenu gross margin estim
note red box indic biolog busi strip
growth engine-i improv output per capita
new entrant clinic servic wuxi consid small scale term
revenu equal iqvia revenu quickli boost sale
margin past year wuxi doubl smo site manag forc
reach person compar lead compani eg iqvia tigerm
still signific potenti wuxi augment well-train team improv
per-capita output
note iqvia revenu averag
note staff number quot wuxi
note staff number appli wuxi calcul
coverag china citi
 countri countri region
wuxi regard key develop strategi clinic servic domest
market plan extend busi line suppli comprehens servic eg
consult file medic write statist analysi site manag
global market compani acceler pace oversea acquisit eg
researchpoint global texa us enhanc compet intern multi-
center servic believ synergi earlier pre-ind servic
wuxi grow becom top-tier clinic cro
wuxi develop stori clinic research servic
vc invest steadi deal flow high return
wuxi seen two phase ventur capit vc invest wuxi healthcar
ventur establish wuxi healthcar ventur ii
establish rais wuxi take wuxi
display foresight invest activ view focus five area
healthcar healthcar servic patient vc provid wuxi fast track
achiev addit return invest ride futur technolog trend
expand reach within healthcar ecosystem
wuxi develop invest vc
wuxi record fair valu gain thank increas valu
hua medicin adagen
fair valu chang available-for-sal financi asset
wuxi invest total compani includ
associ compani joint ventur wuxi success exit seven
project initi invest increas given
deep project pool far-sight manag vc segment continu
creat valu wuxi healthcar ecosystem view
calcul fair valu wuxi vc segment appli book valu
deriv valuat rang usd rmb exchang
rate januari
exampl invest compani
driven attitud everi drug made everi diseas treat
wuxi founder ceo dr ge li put togeth world-class team build
altern engin serv global healthcar industri team
character extens experi senior manag team
averag year experi biotech pharmaceut industri
ventur invest work mnc oversea profound
foresight enabl wuxi captur industri trend client need
gener greater revenu broad rang industri connect help
gather new talent client around compani divers expertis
leader function depart background rang lab test
data manag clinic trial manufactur
qualiti talent attract train retain
wuxi place consider valu talent pool view develop
sound talent system encourag self-develop foster leadership skill
compani announc stock incent plan august plan account
wuxi total share capit direct million stock toward
member staff first grant restrict stock grant
per share august remain stock grant either
restrict stock stock option incent becom exercis
month proport long wuxi achiev revenu
growth less yoy
well-establish mechan attract train retain compet talent
first grant right restrict stock
senior/middl manag technic backbon
co-ceo cfo
secretari board director
share
right grant
total share capit
reserv grant right restrict stock stock option
note assum over-allot option exercis option addit restrict share grant wuxi apptec share
build expand reach within healthcar ecosystem
wuxi focus strengthen comprehens capabl enabl drug
innov lower barrier entri enabl better medic servic
exampl train rural doctor enabl patient receiv new
afford therapi develop pattern ecosystem becom clearer
demonstr compani continu cultiv strateg emerg industri
earn analysi outlook
project revenu compound-annual-growth-rate wuxi support china-
base lab revenu achiev compound-annual-growth-rate driven long-tail client ddsu
busi us-bas lab revenu reach compound-annual-growth-rate fast
develop cell/gen therapi servic clinic servic deliv compound-annual-growth-rate
driven strong demand china global cdmo/cmo
achiev compound-annual-growth-rate driven project move commerci
stage project total revenu
sale
drug analysi test
clinic servic
revenu
drug analysi test
clinic servic
drug analysi test
clinic servic
gross margin shrink slightli view owe greater depreci
new capac improv afterward due economi scale china-
base lab ddsu project move mileston royalti stage fast
develop cell/gen therapi us-bas lab
wuxi gross margin segment
drug analysi test
clinic servic
wuxi expens mainli consist three part sale market expens
gener administr expens includ expens financi
expens gener administr cost unusu high due fee
relat privat paid nyse increas financi expens
mainli rmb appreci sg financi expens
account total revenu expect remain stabl
wuxi sg revenu
wuxi sale market expens
note h-share ipo rais
project compound-annual-growth-rate wuxi net profit support rapid
revenu growth improv gross margin predict ep
assum signific ventur capit fair valu chang contribut
ep
wuxi profit loss statement
sale market expens
revenu
revenu
revenu
revenu
revenu
net profit attribut sharehold
net profit extraordinari item
work capit analysi outlook
current ratio decreas due increas short-
term borrow payabl decreas owe
payment stock option invest new capac acquisit subsidiari
due ipo assum current ratio increas expect slight
decreas
inventori turnov ratio decreas expans
busi expect decreas slightli
account receiv turnov ratio reflect
increas effici compani capit use expect ratio remain
around
account payabl turnov ratio fluctuat slightli
previou two year trade payabl mainli non-interest-bear repay
within normal oper cycl demand expect account payabl turnov
ratio remain within reason rang
consid vari natur busi calcul wuxi equiti valu
combin three part valu tradit cro/cmo busi
pe/dcf valu ddsu mileston royalti incom risk-adjust dcf
valu vc invest project fair equiti valu
wuxi correspond pe base ep
estim wuxi achiev steadi growth reach revenu
yoy estim
correspond normal net profit
item
repres growth yoy
non-recur item includ gain loss dispos non-curr asset
govern subsidi fair valu chang financi asset avail sale
includ fair valu chang vc invest
take global domest leader cro/cmo space compar peer
regard servic content price scheme industri reput growth prospect
share averag pe compar compani a-shar market
due fast growth emerg china market a-shar
investor willing give premium innov share pick wuxi
biolog hk compar peer due lack contract outsourc
provid h-share market wuxi biolog enjoy valuat pe
merit view high compound-annual-growth-rate us share averag
pe compar compani us market much lower
peer a- h-share market given global giant enter
phase matur
comprehens platform provid one-stop drug innov servic think
reason wuxi trade domest peer averag a- h-share
market back fast growth prospect uniqu one-stop servic global
lead posit project fair valu wuxi tradit cro/cmo busi
note lonza price net profit denomin chf market cap number denomin usd base per-usd rate
data januari close
use dcf valuat supplementari method reflect compani long-term
valu assum wacc termin growth suggest fair valu
wuxi tradit cro/cmo busi
depreci amort
 chang work capit
wuxi key assumpt dcf analysi
pv
pv termin valu
debt cost tax
expect wuxi receiv mileston royalti incom ddsu busi
base assumpt wuxi submit ind applic custom
first product royalti structur start commerci
assum termin perpetu growth project fair valu
dcf valuat ddsu busi
pv ncf
pv termin valu
estim fair valu wuxi ventur capit base
assumpt book valu
risk view
compani may lose lead talent manag research may fail
success protect intellectu properti custom may lose
global client intensif sino-u trade war price cut due
intensifi competit compani may suffer exchang rate loss
event currenc fluctuat rmb appreci
chang polici regul china drug market may attenu
drug innov deterior econom environ may hinder
develop pharmaceut biotechnolog compani
wuxi apptec establish privat busi consolid
success list a-shar market sh may wuxi
achiev strong steadi growth driven uniqu comprehens one-stop
servic offer discoveri develop manufactur small molecul
wuxi revenu growth
wuxi net profit growth
note expens paid privat
compani work comprehens coverag across pharmaceut
outsourc chain cro servic becom compani lead segment
revenu though proport cmo/cdmo busi rise
revenu oversea client account major
revenu contribut china custom ramp
revenu breakdown segment
revenu breakdown client landscap
clinic
cro
wuxi establish subsidiari among seven subsidiari five
engag small molecul pre-ind servic shanghai wuhan suzhou tianjin
chengdu wa-int invest hold group wa-hk work
wuxi landscap subsidiari
li along dr ning zhao mr xiaozhong liu mr zhaohui zhang
control sharehold share act concert hold
wuxi experienc four stage develop enter
world drug discoveri pre-clin servic expand
new area medic devic test acquir apptec inc clinic servic
strengthen leadership cro/cmo diversifi invest
captur futur trend opportun long-term growth cell/gen therapi
artifici intellig ventur capit among other
wuxi went privat list a-shar market sh may
expect dynam strategi guid wuxi lead global posit consist
effort enabl drug innov
good sold
sell distrib cost
share assoc
profit tax
depr amort
chg work capit
increas debt
increas equiti
chang cash
start year
effect fx rate chg
view express report accur reflect person view analyst subject secur issuer part
compens analyst directli indirectli relat inclus specif recommend view
